

▶ Medium-Term Vision (Corporate Strategic Plan)


# Restart

Olympus announced a new medium-term vision for the five years from the fiscal year ended March 2013. Acting in accordance with the vision's slogan of "Back to Basics," the Company aims to return to the basic values it had at founding and make a fresh start in order to regain the credibility of its stakeholders, build itself anew, and create new corporate value.

## Corporate Management Policies under the New Management



## Basic Strategies Based on Corporate Management Policies



## Performance Indices and Targets

Performance Indices	FY ended March 2012 (Results)	FY ended March 2013 (Results)	FY ending March 2017 (Target)
Return on invested capital (ROIC)	2.7%	2.7%	10% or more
Operating margin	4.2%	4.7%	10% or more
Free cash flow (Cash flow from operating activities + cash flow from investing activities)	¥(4.8) billion	¥58.7 billion	¥70.0 billion or more
Equity ratio	4.6%	15.5%	30% or more

Results of implementing these basic strategies will be monitored based on four performance indices: "return on invested capital (ROIC)\*," "operating margin," "free cash flow," and "equity ratio."

\* Return on Invested Capital (ROIC)  
ROIC is an index that measures income generated on a company's invested capital (IC). At Olympus, ROIC is calculated using the following assumptions:  
Return (Operating income after taxes) / IC (Shareholders' equity + Interest-bearing debt)

## Progress during the First Year of the Medium-Term Vision and Future Challenges

		Results and Challenges	
<b>1</b> Rebuilding of Business Portfolio / Optimizing Allocation of Management Resources	Medical ▶ P.30	Achieved forecast-exceeding progress and performance	<ul style="list-style-type: none"> <li>Gastrointestinal endoscope field: Introduced new products, such as EVIS EXERA III (Europe and U.S.) and EVIS LUCERA ELITE (Japan), which contributed to increased earnings</li> <li>Surgical device field: Introduced the new VISERA ELITE (Europe, U.S. and Japan) surgical video endoscopy system</li> <li>Commenced business alliance with Sony Corporation and jointly established Sony Olympus Medical Solutions Inc.</li> <li>Management resource allocation: Increased production capacity of major production sites</li> </ul>
	Life Science & Industrial ▶ P.38	Implemented profitability improvement measures in response to deterioration of macroeconomic environment	<ul style="list-style-type: none"> <li>Introduced new products in mainstay model lines on schedule</li> <li>Rationalized production sites and improved operational efficiency by closing a site in the Philippines and consolidating sites in Nagano in preparation for future growth</li> </ul>
	Imaging ▶ P.42	Responded to rapidly changing market conditions and implemented drastic reform of earnings structure	<ul style="list-style-type: none"> <li>Revised product lineup: Shifted to high-value-added products, such as mirrorless cameras</li> <li>Reorganized manufacturing systems</li> <li>Implemented SG&amp;A expense reduction measures</li> </ul>
	Restructuring of non-core businesses	Accelerated reorganization of non-core business domains	<ul style="list-style-type: none"> <li>Transferred Information &amp; Communication Business (September 2012)</li> <li>Liquidated / sold approx. 30 subsidiaries and affiliated companies</li> </ul>
<b>2</b> Review and Reduction of Costs		Achieved certain degree of results, however, continued rationalization of indirect departments needed	<ul style="list-style-type: none"> <li>Reorganized production sites worldwide: 30 ▶ 22 sites</li> <li>Staff size optimization: reduced staff by approx. 6,000* people, achieved target ahead of schedule (includes full-time and part-time employees)</li> </ul>
<b>3</b> Restoration of Financial Health		Made progress in stabilizing operating foundations	<ul style="list-style-type: none"> <li>Increased capital: Commenced capital alliance with Sony</li> <li>Equity ratio: Improved from approx. 5% to over 15%*</li> <li>Interest-bearing debt: Decreased ¥82 billion*</li> </ul>
<b>4</b> Restructuring of Corporate Governance		Strengthened structures for greater effectiveness	<ul style="list-style-type: none"> <li>Instituted new management system clearly separating supervision and business execution</li> <li>Security on Alert designation removed on June 11, 2013</li> </ul>

\* Compared with March 31, 2012

## Financial Plans

	FY ending March 2015		FY ending March 2017	
	Previous target	Revised target	Previous target	Revised target
Net sales	¥1,010 billion	¥760 billion	¥1,160 billion	¥920 billion
Operating income (Operating margin)	¥90 billion 9%	¥93 billion 12%	¥130 billion 11%	¥143 billion 16%
Ordinary income (Ordinary income ratio)	¥70 billion 7%	¥70 billion 9%	¥115 billion 10%	¥125 billion 14%
Net income (Net income ratio)	¥40 billion 4%	¥45 billion 6%	¥85 billion 7%	¥85 billion 9%

### Notes:

- Figures for previous targets are those from when the medium-term vision was initially announced on June 8, 2012. Revised target figures reflect the revision released on May 15, 2013.
- Previous foreign exchange assumptions called for exchanges rates of ¥80 to US\$1 and ¥100 to 1 EUR. Revised assumptions projected exchanges rates of ¥90 to US\$1 and ¥120 to 1 EUR.